Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLG802 in recurrent advanced solid tumors
NCT03164603Phase 1Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jun 2017
- Primary completion
- Apr 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nlg802 in solid tumor, sponsored by Lumos Pharma, Inc. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events up to 2 years. Started Jun 2017; status: completed.
02
Drugs
nlg802
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03164603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164603.